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Summary
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with 
reproduction, and aﬀ ect breast cancer risk. Our aim was to assess the strengths of their eﬀ ects and determine whether 
they depend on characteristics of the tumours or the aﬀ ected women.
Methods Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 
306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. 
We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by 
tumour histology and by oestrogen receptor expression.
Findings Breast cancer risk increased by a factor of 1·050 (95% CI 1·044–1·057; p<0·0001) for every year younger at 
menarche, and independently by a smaller amount (1·029, 1·025–1·032; p<0·0001), for every year older at menopause. 
Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 
45–54 years 1·43, 1·33–1·52, p<0·001). All three of these associations were attenuated by increasing adiposity among 
postmenopausal women, but did not vary materially by women’s year of birth, ethnic origin, childbearing history, 
smoking, alcohol consumption, or hormonal contraceptive use. All three associations were stronger for lobular than 
for ductal tumours (p<0·006 for each comparison). The eﬀ ect of menopause in women of an identical age and trends 
by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen receptor-negative 
disease (p<0·01 for both comparisons).
Interpretation The eﬀ ects of menarche and menopause on breast cancer risk might not be acting merely by lengthening 
women’s total number of reproductive years. Endogenous ovarian hormones are more relevant for oestrogen receptor-
positive disease than for oestrogen receptor-negative disease and for lobular than for ductal tumours.
Funding Cancer Research UK.
Introduction
Menarche and menopause are markers of onset and 
cessation, respectively, of ovarian and related endocrine 
activity associated with reproduction. During women’s 
reproductive years (broadly the time between menarche 
and menopause) the ovary produces steroid hormones 
that directly aﬀ ect development and function of the 
breast. Early menarche and late menopause are known to 
increase women’s risk of developing breast cancer. 
To assess reliably the strengths of these associations and 
whether they vary by tumour subtype or by characteristics 
of aﬀ ected women requires large numbers, and we 
address these questions by combining information from 
more than 100 epidemiological studies. Combining 
individual participant data from many studies not only 
increases statistical power but also permits similar 
deﬁ nitions and similar analytical methods to be used 
across studies.
Methods
Search strategy and selection criteria
This collaboration began in 1992, and has published on 
breast cancer risk associated with use of hormonal 
therapies and childbearing practices.1–4 Potentially eli gible 
epidemiological studies have been sought at regular 
intervals by computer-aided literature searches, by written 
communication and discussions with col leagues, and by 
discussions at scientiﬁ c meetings, including collaborators’ 
meetings in Oxford in 1993, 1995, 2000, 2005, and 2011 
(appendix p 3 shows search strategy and selection 
criteria). Principal investigators of eligible studies were 
invited to join the collaboration.
Data extraction
Cases were women with invasive breast cancer and 
controls were women without breast cancer. So that 
similar analytical methods could be used across studies, 
we incorporated cohort studies using a nested case–
control design, in which up to four controls were selected 
at random, matched at follow-up to age of the case at 
cancer diagnosis and, where appropriate, by broad 
geographical region. Data for a range of sociodemo-
graphic, reproductive, and other behavioural factors, 
covering the time period to onset of disease for cases and 
to an equivalent time for controls, were sought from 
principal investigators (appendix p 3).
See Online for appendix
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We included studies in these analyses if individual 
data had been provided for women’s menopausal 
status, age at menarche and, if appropriate, age at 
menopause, and whether or not they had had a 
hysterectomy or a bilateral oophorectomy. Women who 
had had a natural menopause or who had had a bilateral 
oophorectomy before their natural menopause were 
classiﬁ ed as postmenopausal, but those who had had a 
hysterectomy without bilateral oophorectomy before 
their natural menopause were classiﬁ ed as being of 
unknown menopausal status (because hysterectomy 
can mask cessation of ovarian activity). Otherwise, we 
took deﬁ nitions used by principal investigators to 
classify each woman by her age at menarche, 
menopausal status and, for postmenopasual women, by 
her age at menopause. Women with unknown meno-
pausal status or unknown ages at menarche or 
menopause were excluded from analyses, as were 
women who had used menopausal hormone therapy, 
since such use can mask the onset of menopause and 
modify associations between hormonal factors and 
breast cancer risk.1
We also sought information about tumour charac-
teristics—ie, about oestrogen receptor status and about 
tumour histology. We used information provided by 
principal investigators to classify tumours as oestrogen 
receptor-positive or oestrogen receptor-negative, and as 
ductal, lobular, or of other histology.
Statistical analysis
We did all analyses using conditional logistic regression, 
similar in principle to the Mantel-Haenszel stratiﬁ cation 
technique used in previous reports from this 
collaboration.1–6 When two groups were compared odds 
ratios (ORs, described as relative risks [RRs] when cases 
and controls are compared) and standard CIs are given. 
When more than two groups were compared, we 
estimated variances for every group, treating the ORs or 
RRs as ﬂ oating absolute risks,7 because this method 
enables valid comparisons between any two groups, even 
if neither is the baseline group. This method does not 
alter risk estimates, but yields variances for each non-
baseline group that are slightly smaller than the variances 
calculated with conventional methods (because these 
include the variance of the baseline group) and we used 
these variances to calculate group-speciﬁ c CIs. Any 
comparison between two risk estimates must take  the 
variation in each group into account.
Analyses of the association between various factors 
and women’s age at menarche and age at menopause 
were restricted to controls, and we calculated ORs 
stratifying by study, by centre within study, and where 
appropriate by age at diagnosis (≤20 years, and then in 
3 year age groups, 21–23 years to 87–89 years); by year 
of birth (<1920, 1920–29, 1930–39, 1940–49, and ≥1950); 
by parity and age when ﬁ rst child was born (nulliparous 
women were a separate stratum and parous women 
were cross-classiﬁ ed by parity [1–2, ≥3] and age at ﬁ rst 
birth [<20 years, 20–29 years, ≥30 years]); by current 
body-mass index (BMI; <25 kg/m², 25–29 kg/m², 
≥30 kg/m²); by height (<160 cm, 160–164 cm, ≥165 cm); 
by smoking (never, past, present); and by alcohol 
consumption per week (<50 g and ≥50 g). Women with 
unknown values for any adjustment variable were 
assigned to separate strata.
Analyses of the RR of breast cancer were routinely 
stratiﬁ ed by the same factors as described above. The 
eﬀ ects on the main ﬁ ndings of other potential 
confounding factors (ethnic origin, hormonal 
contraceptive use, family history of breast cancer) were 
also examined. We restricted analyses comparing breast 
cancer risk in premenopausal, perimenopausal, and 
postmenopausal women to women aged 45–54 years 
(since each category is represented in this narrow age 
band) and we used the same stratiﬁ cations as described 
above, except that age was stratiﬁ ed by single years. We 
stratiﬁ ed analyses relating to tumour characteristics by 
Figure 1: Cumulative distribution of (A) age at menarche and (B) age at 
natural menopause
Data are for women without breast cancer—ie, controls. Results for age at 
menarche are based on data from 306 068 women. Results for age at 
menopause are based on data from 157 272 postmenopausal women aged older 
than 55 years at the time of reporting their age at menopause.
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Number with 
menarche at age 
11 years or
 younger/≥12 years
OR and 99% gs CI 
for menarche 
at age 11 years or 
younger vs later
Number with 
menopause at 
age 52 years or 
older/<52 years
OR and 99% gs CI 
for menopause at 
age 52 years or 
older vs earlier
Year of birth                                     
<1930                                             
1930–39                                         
1940–49                                         
Parity                                            
Nulliparous                                       
1–2                                               
≥3                                                
Age at ﬁrst birth (years)                                    
<20                                               
20–29                                             
≥30                                               
Height                                            
<160 cm                                           
160–164 cm                                           
≥165 cm                                           
BMI (young adult)                     
<20 kg/m²
20–24 kg/m2
≥25 kg/m2
BMI (current)                         
<25 kg/m2
25–29 kg/m2
≥30 kg/m2
Use of hormonal contraceptives                    
Never                                             
<5 years                                          
≥5 years                                          
Smoking                                           
Never                                             
Past                                              
Present                                           
Alcohol                                           
None                                              
<50 g/week                                        
≥50 g/week                                        
Menopausal status                                 
Premenopausal                                      
Perimenopausal                                    
Postmenopausal                                    
Age at menarche (years)                                   
<12                                               
12–13                                             
≥14                                               
 10 685/64 654
15 412/78 168
16 864/78 570
 
 6807/32 518
18 501/103 950
 15 916/99 132
 
6580/29 797
29 032/156 742
4483/25 489
16 383/71 426
 13 977/65 134
16 970/89 057
 
 6430/43 614
 12 219/57 048
 3280/9195
 20 080/125 820
 14 356/61 182
 10 748/29 645
 
24 161/130 862
10 603/48 568
9429/41 976
 
23 244/124 558
12 241/48 913
 9210/39 536
 
 15 155/87 486
19 427/85 367
7230/32 680
 
 7190/38 021
904/4793
2940/15 993
 
Not applicable
Not applicable
Not applicable
1·00 (0·015)
1·25 (0·010)
1·63 (0·017)
1·00 (0·019)
0·97 (0·009)
0·91 (0·011)
1·00 (0·021)
0·82 (0·007)
0·80 (0·020)
1·00 (0·012)
0·82 (0·011)
0·69 (0·009)
1·00 (0·018)
1·53 (0·016)
2·38 (0·046)
1·00 (0·011)
1·45 (0·014)
2·14 (0·023)
1·00 (0·014)
1·05 (0·017)
1·04 (0·018)
1·00 (0·010)
1·06 (0·014)
1·14 (0·017)
1·00 (0·014)
1·00 (0·012)
0·97 (0·019)
1·00 (0·022)
1·21 (0·073)
1·11 (0·041)
Not applicable
Not applicable
Not applicable
 20 827/39 876
 19 532/36 579
 5115/9028
 
 4784/10374
 16 474/31 794
 19 803/38 650
 
 4292/9881
 31 954/55 077
 5013/8769
 15 659/30 376
 14 391/24 802
 18 005/29 738
 
 7472/13597
 11 719/20 424
 1995/3613
 
 21 812/40 961
 15 778/26 898
 8692/14 002
 
 30 870/57 025
 5775/10 437
 5788/10 392
 
 28 021/44 534
 11 092/18 898
 5567/14 414
 
 15 214/31 621
 19 906/30 926
 7581/12 158
 
Not applicable
Not applicable
Not applicable
 8878/13 308
 22 845/42 688
 18 311/34 522
1·00 (0·016)
0·87 (0·007)
0·87 (0·022)
1·00 (0·023)
1·25 (0·013)
1·34 (0·013)
1·00 (0·027)
1·12 (0·009)
1·13 (0·027)
1·00 (0·014)
1·03 (0·013)
1·06 (0·013)
1·00 (0·020)
1·10 (0·016)
1·14 (0·041)
1·00 (0·011)
1·07 (0·013)
1·14 (0·019)
1·00 (0·014)
1·00 (0·025)
0·93 (0·024)
1·00 (0·011)
0·80 (0·014)
0·56 (0·016)
1·00 (0·016)
1·14 (0·014)
1·21 (0·024)
Not applicable
Not applicable
Not applicable
1·00 (0·022)
1·06 (0·012)
1·09 (0·016)
0 1·0 2·0 3·0 0 1·0 2·0 3·0
B   Correlates of late natural menopauseA   Correlates of early menarche
OR (gs SE)OR (gs SE)
Figure 2: Correlates of various factors with (A) early menarche and (B) late natural menopause
Data are for women without breast cancer—ie, controls. OR calculations were stratiﬁ ed by study and, where appropriate, by age at diagnosis, year of birth, parity, age at ﬁ rst birth, smoking, alcohol 
consumption, height, and current BMI (results for BMI as a young adult are not stratiﬁ ed by current BMI). Results for age at menopause are restricted to postmenopausal women without breast cancer 
aged 55 years or older at the time they reported their age at menopause. OR=odds ratio. gs=group speciﬁ c. BMI=body-mass index.
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study, centre within study, age at diagnosis in single 
years, and year of birth, and adjusted by parity, age at ﬁ rst 
birth, BMI, smoking, and alcohol consumption, also 
using the same categories as described previously.
We calculated RRs for breast cancer per 1 year younger 
at menarche and per 1 year older at menopause by linear 
regression, using the mean age within each category. We 
made comparisons across diﬀ erent subgroups of women 
using standard χ² tests for heterogeneity, calculated from 
the change in log likelihood on addition of extra terms. 
Signiﬁ cance tests for heterogeneity by tumour subtype 
were based on analyses within cases only (because 
controls provide no additional information), stratiﬁ ed by 
age, study, and BMI and adjusted for other variables 
listed previously. We did our analyses with STATA 
(version 11).
When results for large numbers of subgroups are 
presented in the ﬁ gures 99% CIs (or group-speciﬁ c 
99% CIs) are given, to take account of multiple testing. 
In the text all CIs quoted are 95% CIs.
Role of the funding source
The funders had no role in study design, data collection, 
analysis, or interpretation of data, preparation of the 
report, or decision to publish. All members of the 
analysis and writing committee (VB, DB, RP, KP, GR) 
had access to the raw data and are responsible for the 
ﬁ nal submission for publication.
Results
Overall 117 studies, together including 118 964 women 
with breast cancer (cases) and 306 091 without the disease 
(controls), were included in these analyses. Appendix 
pp 4–5 show details of every contributing study, including 
a reference to each, and study-speciﬁ c information about 
the women included in the analyses. The 117 studies 
were done in 35 countries, mostly in Europe or North 
America. Median year of birth of women with breast 
cancer was 1939 (IQR 1930–1948), and median year of 
cancer diagnosis was 1993 (1986–1998). Median age at 
cancer diagnosis was 54 years (IQR 44–64).
Figure 1A shows the distribution of age at menarche 
reported by controls—ie, women without breast cancer. 
Their mean age at menarche was 13·1 years (SD 1·7), with 
almost two-thirds (65%, 198 113 of 306 068) reporting 
menarche at ages 12, 13, or 14 years. Only 16% (49 464) of 
the controls reported menarche at age 11 years or younger 
and 19% (58 514) reported menarche at age 15 years or 
older. Having early menarche was associated with many 
factors known to aﬀ ect breast cancer risk, including parity, 
Figure 3: Relative risk of breast cancer by (A) age at menarche and (B) age at menopause
Calculated stratifying by study, age, year of birth, parity, age at ﬁ rst birth, smoking, alcohol consumption, height, and 
current body-mass index. RR=relative risk. gs=group speciﬁ c.
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<11 ( 9·7)
5511/11 685
1·19 
(1·13–1·25)
11 (11·0)
15 855/37 779
1·09 
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12 (12·0)
25 806/61 512
1·07 
(1·05–1·09)
13 (13·0)
31 759/83 389
1·00
(0·98–1·02)
14 (14·0)
20 599/53 212
0·98 
(0·96–1·00)
15 (15·0)
10 576/31 390
0·92 
(0·89–0·95)
≥16 (16·6)
8858/27 124
0·82 
(0·79–0·85)
35 40 45 50 55
Age at menopause (years)
<40 (35·3)
2397/7741
0·67 
(0·62–0·73)
40–44 (41·9)
5516/18 544
0·73 
(0·70–0·77)
45–49 (47·2)
17 336/52 040
0·86 
(0·84–0·89)
50–54 (51·5)
28 197/75 944
1·00 
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≥55 (56·1)
6891/16 144
1·12 
(1·07–1·17)
0·6
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0·6 Figure 4: Relative risk of breast cancer (A) per year younger at menarche and 
(B) per year older at menopause, in various subgroups and by tumour 
characteristics
Relative risks are calculated stratifying by study and age, and where appropriate, 
by year of birth, parity, age at ﬁ rst birth, smoking, alcohol consumption, height, 
and current BMI (results for BMI as a young adult are not stratiﬁ ed by current 
BMI). RR=relative risk. BMI=body-mass index. ER=oestrogen receptor. 
*Subgroup analyses for age at menarche are for age at menopause <50 vs 
≥50 years in postmenopausal women; and for age at menopause are for age at 
menarche <13 vs ≥13 years. †Case-case comparisons stratiﬁ ed by study, age and 
year of birth, and adjusted by parity, age at ﬁ rst birth, smoking, alcohol 
consumption, height, and current BMI. 
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Cases/controls RR (SE) RR* of breast cancer per 1 year 
younger at menarche and 99% CI
Cases/Controls RR (SE) ReR* of breast cancer per 1 year older at 
menopause and 99% CI
All women 
Women's characteristics 
Year of birth 
   <1930 
   1930–39 
   ≥1940 
   Heterogeneity test: 
Age at diagnosis and menopausal status
   Premenopausal 
      Age <45 (mean age 38) 
      Age 45–54 (mean age 49) 
      Heterogeneity test: 
   Postmenopausal
      Age 45–54 (mean age 51) 
      Age 55–64 (mean age 60) 
      Age ≥65 (mean age 70) 
      Heterogeneity test: 
Ethnicity 
   White
   Non-white
   Heterogeneity test: 
Parity
   Nulliparous 
   Parous
   Heterogeneity test: 
Age at ﬁrst birth
   <25 
   ≥25 
   Heterogeneity test: 
Height
   <165 cm 
   ≥165 cm 
   Heterogeneity test: 
BMI (young adult)
    <20 kg/m
    ≥20 kg/m
    Heterogeneity test: 
BMI (current) 
   Premenopausal 
      <25 kg/m²
      ≥25 kg/m²
      Heterogeneity test: 
   Postmenopausal
      <25 kg/m²
      ≥25 kg/m²
      Heterogeneity test: 
Use of hormonal contraceptives
   Never 
   Ever
   Heterogeneity test: 
Smoking 
   Never 
   Past
   Present
   Heterogeneity test: 
Alcohol 
   None
   <50 g/week
   ≥50 g/week
   Heterogeneity test: 
Mother or sister with breast cancer 
   No
   Yes 
   Heterogeneity test: 
Age at menopause/menarche*
   Younger 
   Older 
   Heterogeneity test: 
Tumour characteristics
ER status 
   Negative
   Positive  
   Case-case comparison† for ER+ vs ER–: 
Histology 
   Ductal
   Lobular 
   Other 
   Case-case comparison† for lobular vs ductal:
 118 964/306 091
 28 155/69 358
 33 091/91 151
 57 718/145 582
 28 920/59 351
 20 744/45 211
 8170/18 933
 25 434/71 534
 26 175/78 843
 72 679/166 317
 19 743/61 857
 18 024/39 325
 93 330/237 499
 50 336/147 661
 46 098/104 462
 64735/166920
 45659/106027
 24 993/50 044
 36 429/81 742
 31 476/62 187
 14 375/33 799
 25 093/75 619
 28 998/77 573
 61 516/155 023
 47 814/120 814
 57 473/147 802
 25 139/61 154
 21 631/48 746
 35 686/102 641
 38 046/104 794
 20 159/39 910
 84 815/217 296
 13 738/21 963
 25 249/78 325
 35 088/92 088
 7370/140 686
 19 875/140 686
 54 713/23 0370
 6801/23 0370
 12 258/23 0370
1·050 (0·003)
1·049 (0·007)
1·047 (0·006)
1·054 (0·005)
χ²₂ =0·8, p=0·7
1·071 (0·007)
1·057 (0·009)
χ²₁ =1·5, p=0·2
1·083 (0·016)
1·044 (0·007)
1·039 (0·007)
χ²₂ =6·3, p=0·04
1·052 (0·005)
1·063 (0·008)
χ²₁ =1·3, p=0·2
1·060 (0·010)
1·051 (0·003)
χ²₁ =0·7, p=0·4
1·047 (0·005)
1·050 (0·005)
χ²₁ =0·2, p=0·7
1·050 (0·004)
1·049 (0·005)
χ²₁ =0·05, p=0·8
1·062 (0·008)
1·052 (0·006)
χ²₁ =0·9, p=0·3
1·069 (0·007)
1·045 (0·011)
χ²₁ =3·2, p=0·07
1·057 (0·007)
1·031 (0·006)
χ²₁ =7·4, p=0·006
1·049 (0·005)
1·051 (0·006)
χ²₁ =0·05, p=0·8
1·054 (0·005)
1·036 (0·008)
1·042 (0·009)
χ²₂ =4·0, p=0·1
1·050 (0·006)
1·036 (0·006)
1·044 (0·010)
χ²₂ =2·5, p=0·3
1·048 (0·004)
1·001 (0·017)
χ²₁ =6·7, p=0·01
1·039 (0·009)
1·049 (0·007)
χ²₁ =0·9, p=0·4
1·049 (0·009)
1·049 (0·005)
p=0·7
1·035 (0·003)
1·073 (0·009)
1·044 (0·007)
p=0·00001
 60337/170413
 26 440/63 448
 22 015/67 940
 11 882/39 025
Not applicable
Not applicable
 8170/18 933
 25 434/71 534
 26 175/78 843
 37266/95633
 8643/28220
 8548/18 817
 45 816/129 164
 25 673/82 889
 22 635/57 460
 34 901/101 348
 21 953/57 931
 10 720/26 047
 17 335/45 696
Not applicable
Not applicable
 25 093/75 619
 28 998/77 573
 40 366/105 373
 13 427/44 400
 30 245/85 663
 13 095/35 989
 10 044/25 782
 19 282/57 247
 19 494/60 135
 10 498/23 605
 41 877/115 443
 7654/14 052
 22 442/59 777
 37 895/110 636
 3412/86 191
 11 156/86 191
 28 603/136 099
 3766/136 099
 6711/136 099
1·029 (0·002)
1·026 (0·003)
1·033 (0·003)
1·023 (0·004)
χ²₂ =5·1, p=0·08
Not applicable
Not applicable
1·034 (0·007)
1·030 (0·003)
1·027 (0·002)
χ²₂ =1·4, p=0·5
1·028 (0·002)
1·027 (0·005)
χ²₁ =0·1, p=0·7
1·025 (0·005)
1·027 (0·002)
χ²₁ =0·3, p=0·6
1·023 (0·002)
1·031 (0·003)
χ²₁ =4·5, p=0·03
1·027 (0·002)
1·030 (0·003)
χ²₁ =0·6, p=0·5
1·026 (0·004)
1·024 (0·003)
χ²₁ =0·05, p=0·8
Not applicable
Not applicable
1·033 (0·003)
1·024 (0·002)
χ²₁ =6·9, p=0·008
1·029 (0·002)
1·025 (0·005)
χ²₁ =0·6, p=0·4
1·027 (0·002)
1·031 (0·004)
1·031 (0·005)
χ²₂ =1·3, p=0·5
1·026 (0·003)
1·033 (0·003)
1·023 (0·005)
χ²₂ =3·3, p=0·2
1·030 (0·002)
1·025 (0·008)
χ²₁ =0·3, p=0·6
1·030 (0·003)
1·029 (0·002)
χ²₁ =0·09, p=0·8
1·020 (0·004)
1·031 (0·003)
p=0·01
1·026 (0·002)
1·036 (0·004)
1·024 (0·003)
p=0·006
0·975 1·0 1·025 1·05 1·075 1·1 0·975 1·0 1·025 1·05 1·075 1·1
B   Age at menopauseA   Age at menarche
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age at ﬁ rst birth, height, and BMI (ﬁ gure 2A). Increasing 
adiposity, both as a young adult and currently, showed the 
strongest associations with early menarche. Associations 
with late menarche were generally the con verse of 
associations with an early menarche (appendix p 7).
The younger women were at menarche, the greater was 
their subsequent risk of breast cancer, the RR increasing 
by a factor of 1·050 (95% CI 1·044–1·057, p<0·0001) for 
every year younger at menarche (ﬁ gure 3A). Results in 
Figure 3A were stratiﬁ ed by study, age, year of birth, 
parity and age at ﬁ rst birth, height, current BMI, 
smoking, and alcohol consumption. Additional 
adjustment (either individually or simultaneously) by 
ethnic origin, hormonal contraceptive use, and family 
history of breast cancer, altered the excess RR estimate by 
less than 1% (data not shown).
To assess consistency of ﬁ ndings, we calculated the RR 
of breast cancer per year younger at menarche for 
34 subgroups of women, subdivided by 14 of their personal 
characteristics: year of birth, age at diagnosis and 
menopausal status, ethnic origin, parity, age at ﬁ rst birth, 
height, BMI as a young adult, current BMI, use of oral 
contraceptives, smoking, alcohol consumption, family 
history of breast cancer, menopausal status and, for 
postmenopausal women, their age at menopause 
(ﬁ gure 4A). Both among premenopausal and among 
postmenopausal women, increasing BMI seemed to 
attenuate the relevance of age at menarche, but this 
attenuation was signiﬁ cant only among postmenopausal 
women (hetero geneity p=0·006). We noted some 
weakening of the association with age at menarche by 
attained age in postmenopausal women (heterogeneity 
p=0·04; trend p=0·02) and family history of breast cancer 
(heterogeneity p=0·01), but for all other personal 
characteristics examined heterogeneity across subgroups 
was not signiﬁ cant. The ﬁ ndings were not dominated by 
the results in any particular study (appendix pp 8–10) and 
there was no signiﬁ cant heterogeneity in the ﬁ ndings by 
study design (appendix p 6).
Of the 117 contributing studies, 85 provided some 
information about tumour characteristics (appendix 
pp 4–5), and ﬁ gure 4A shows the RRs per year younger at 
menarche for various tumour subtypes. The association 
with age at menarche was signiﬁ cantly stronger for 
lobular than ductal tumours (heterogeneity p=0·0001), 
but there were no signiﬁ cant diﬀ erences by oestrogen 
receptor status. Cross-classiﬁ cation by both oestrogen 
receptor status and tumour histology did not show any 
further interaction (appendix p 6).
Figure 1B shows the cumulative distribution of the 
reported age at natural menopause among postmeno-
pausal controls. Their mean age at natural menopause 
was 49·3 years (SD 4·6), with 15% (26 285 of 170 413) 
reporting menopause before age 45 years, 75% (127 984) 
between the ages 45 and 54 years, and 10% (16 144) at age 
55 years or older. There was little association between 
women’s reported ages at natural menopause and at 
menarche (correlation coeﬃ  cient=0·001). Having a late 
menopause was weakly associated with women’s year of 
birth, childbearing history, BMI, and alcohol consump-
tion, but the strongest association observed was with 
smoking, which was negatively associated with a late 
Figure 5: Hormone concentrations and breast cancer risk at around the time of the menopause
(A) Circulating oestradiol concentrations, in the years before and after menopause, calculated from published 
data.7 (B) RR of breast cancer in women aged 45–54 years, by menopausal status. (C) RR of breast cancer in women 
aged 45–54 years by menopausal status and current BMI. RRs stratiﬁ ed by study, age at diagnosis in single years, 
year of birth, parity, age at ﬁ rst birth, smoking, alcohol consumption, height, and current BMI. RR=relative risk. 
gs=group speciﬁ c. BMI=body-mass index. *Results for breast cancer risk are plotted against the time between 
menopause and the diagnosis of breast cancer for postmenopausal women, and against an estimate of that time 
for premenopausal and perimenopausal women. The postmenopausal women aged 45–54 years in these analyses 
reported that their menopause had occur red 4·6 years previously, on average. The premenopausal women aged 
45–54 years in these analyses would be expected to reach their menopause in the next 2·7 years, on average (this 
estimate is based on the age distribution of the premenopausal women in these analyses and the age distribution 
of women’s ages at menopause shown in ﬁ gure 1B). Perimenopausal women might be expected to reach their 
menopause in the next 6 months, on average.
A   Oestradiol concentrations at around the time of menopause (from published data7)
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menopause. (ﬁ gure 2B). Associations with an early 
meno pause were generally the converse of those 
associated with a late menopause (appendix p 7).
Ovarian production of hormones decreases rapidly at 
around the time of menopause, as is shown in ﬁ gure 5A, 
using published data from a cohort study of women who 
were premenopausal at entry and who had repeated 
measures of serum oestradiol until after the menopause.8 
The short-term eﬀ ect of these changes on breast cancer risk 
can be assessed by restricting analyses to the 31 000 cases 
and 70 000 controls aged 45–54 years (since pre menopausal, 
peri menopausal, and postmenopausal women are 
represented in this age group) and by stratifying analyses 
by single years of age (so that women of identical ages are 
being compared). Among such women, breast cancer risk 
was greater among premeno pausal than postmenopausal 
women (RR 1·43, 95% CI 1·33–1·52, p<0·0001), with the 
risk for perimenopausal women being between the other 
two (ﬁ gure 5B; p<0·001 for all comparisons).
The consistency of the ﬁ nding of a greater risk of breast 
cancer among premenopausal than post menopausal 
women of the same age was examined across 
30 subgroups of women, subdivided by 13 of their 
characteristics (appendix p 11). There was little hetero-
geneity across most subgroups, except that women’s 
adiposity attenuated the association. This ﬁ nding reﬂ ects, 
at least in part, known diﬀ erences between premenopausal 
and postmenopausal women in the relation between 
their current BMI and breast cancer risk, as shown in 
ﬁ gure 5C. Among premenopausal women, those who 
were overweight or obese (BMI ≥25 kg/m²) had a lower 
risk of breast cancer than leaner women (BMI <25 kg/m²), 
whereas the reverse was observed among postmenopausal 
women. Hence, the RR of breast cancer after the 
menopause decreases more rapidly in lean than in 
overweight or obese women (p<0·0001).
The proportion of diﬀ erent types of breast cancer varies 
by age and by menopausal status (ﬁ gure 6). For tumours of 
known oestrogen receptor status, the proportion that is 
oestrogen receptor-positive increases with age in both 
premenopausal and postmenopausal women. However, at 
ages 45–54 years, where both premenopausal and 
postmenopausal women are rep resented, a sudden 
decrease occurs at menopause in the proportion of 
oestrogen receptor-positive tumours. Similarly, the 
proportion of tumours with lobular histology increases 
with age, with a sudden decrease around the time of 
menopause. After adjusting by single years of age and 
other potential confounding factors, the heterogeneity at 
ages 45–54 years between premenopausal and 
postmenopausal women is highly signiﬁ cant both for 
oestrogen receptor status (hetero geneity p=0·003) and for 
tumour histology (heterogeneity p<0·0001, appendix p 11).
In analyses restricted to postmenopausal women, 
the RR of breast cancer increased by a factor of 
1·029 (1·025–1·032, p<0·0001) for every year older at 
menopause (ﬁ gure 3B). The ﬁ ndings in ﬁ gure 3B were 
stratiﬁ ed by study, year of birth, age, parity and age at ﬁ rst 
birth, height, current BMI, smoking, and alcohol 
consumption. Additional adjustment by ethnic origin, age 
at menarche, family history of breast cancer, and hormonal 
contraceptive use (both individually and simultaneously) 
altered the excess RR estimate by less than 1%  (data not 
shown). RRs did not diﬀ er signiﬁ cantly between women 
with a natural menopause (1·030, 1·026–1·034) and 
bilateral oophor ectomy (1·019, 1·004–1·034, heterogeneity 
p=0·2; appendix p 12).
The association between age at menopause and breast 
cancer risk was examined in 30 subgroups and did not 
vary signiﬁ cantly across 11 of the 13 characteristics 
examined (ﬁ gure 4B). The association was attenuated by 
women’s current BMI (heterogeneity p=0·008) and by 
age at ﬁ rst birth (heterogeneity p=0·03). The relation 
between breast cancer risk and increasing age at 
Figure 6: Breast cancer by tumour characteristics and by women’s age and 
menopausal status
(A) Oestrogen receptor-positive (ER+). (B) Lobular histology. Results are shown 
for age groups <40 years, 40–44 years, 45–54 years, 55–59 years, 60–64 years, 
and ≥65 years, and plotted against the mean age of women with breast cancer 
in each age group.
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menopause was signiﬁ cantly greater for oestrogen 
receptor-positive disease than for oestrogen receptor-
negative disease (p=0·01), and for lobular than for ductal 
tumours (heterogeneity p=0·006). Cross-classiﬁ cation by 
both oestrogen receptor status and tumour histology did 
not show any further interaction (appendix p 6). The 
ﬁ ndings were not dominated by the results in any 
particular study (appendix pp 13–15) and there was no 
signiﬁ cant variation by study design (appendix p 6).
Among postmenopausal women, for whom the eﬀ ect 
on breast cancer risk per year younger at menarche can 
be directly compared to the eﬀ ect per year older at 
menopause, breast cancer risk increased by a sig-
niﬁ cantly greater amount per year of menarche than 
per year of menopause (1·045 [1·036–1·054] vs 1·029 
[1·025–1·032]; heterogeneity p=0·001).
Discussion
This worldwide collaboration has brought together and 
reanalysed individual participant data for 120 000 women 
with breast cancer and 300 000 controls without the disease 
from 117 epidemiological studies in 35 countries (panel).
While conﬁ rming that early menarche and late 
menopause increase breast cancer risk, we showed that 
these eﬀ ects were not equivalent, in that the excess risk 
associated with lengthening women’s reproductive years 
by one year at menarche was greater than the excess 
associated with one year’s lengthening at menopause. 
We also found that oestrogen receptor-positive and 
lobular breast cancers are strongly aﬀ ected by women’s 
menopausal status, and by their age.
The production of steroid hormones by the ovary 
begins at around the time of menarche and decreases 
rapidly at around the time of menopause. Most women 
become menopausal between the ages of 45 and 54 years. 
By restricting analyses to the 31 000 women with breast 
cancer in this narrow age range and stratifying by single 
years of age (and by other potential confounding factors), 
valid comparisons can be made of the short-term eﬀ ect 
of the menopause, and breast cancer risk was about 40% 
higher in premenopausal than in postmenopausal 
women of the same age. Since the postmenopausal 
women had reached their menopause only an average 
4·6 years previously, the ﬁ ndings indicate a rapid decline 
in breast cancer risk in women of identical ages soon 
after menopause. This ﬁ nding probably explains the 
ﬂ attening of the age-incidence curve at around age 
50 years, the so-called Clemmesen’s hook,9 frequently 
observed in populations before the widespread use of 
hormonal therapies and screening.
There is accumulating evidence that oestrogen receptor-
positive and lobular breast cancers are more sensitive to 
ovarian hormones than are oestrogen receptor-negative 
and ductal cancers. Not only are oestrogen receptor-
positive and lobular tumours strongly aﬀ ected by the 
menopause, as we have shown, but postmenopausal 
women who use hormone therapy have a greater increase 
in oestrogen receptor-positive than oestrogen receptor-
negative tumours and in lobular than ductal breast 
cancers.10,11 Furthermore, oestrogen-blocking treatments 
improve survival for oestrogen receptor-positive, but not 
for oestrogen receptor-negative breast cancer.12
Women’s adiposity was consistently shown to attenuate 
associations between menopause and breast cancer risk. 
Circulating oestradiol concentrations increase as 
postmenopausal women’s BMI increases.13 That the RR 
of breast cancer risk falls more rapidly after the 
menopause in lean than in overweight and obese women 
is likely to reﬂ ect, at least in part, diﬀ erences in oestradiol 
concentrations between such women. Oestradiol con-
centrations in postmenopausal women are greater the 
younger they were at menarche,14 and this might, in part, 
account for the associations recorded between age at 
menarche and breast cancer risk.
Although a woman’s age at menarche does not coincide 
precisely with the onset of breast development, the two 
are highly correlated.15 Breast cancer is almost unknown 
before menarche and extremely rare soon afterwards, 
making it eﬀ ectively impossible to study the short-term 
eﬀ ects of the hormonal changes associated with 
menarche by comparing breast cancer risk in women of 
identical ages before and soon after menarche.
Panel: Research in context
Systematic review
The Collaborative Group on Hormonal Factors in Breast Cancer began in 1992. Since then 
published literature on epidemiological studies of breast cancer has been identiﬁ ed using 
electronic searches (Medline, Embase, and PubMed, 1998–2011; using combinations of 
the search terms “breast cancer”, “risk”, “epidem*”, and “hormones”), supplemented by 
hand searching in review articles. Eligible studies needed to have obtained individual 
information about reproductive factors and about use of hormonal therapies, from at 
least 400 women with breast cancer and similar information from controls without the 
disease. Studies that had obtained relevant data, but had not published any results for 
breast cancer were sought by correspondence with colleagues, by discussions at 
collaborators meetings, and by electronic searches using additional terms “cohort”, 
“prospective”, “women”, and “cancer risk”.
117 eligible studies were included and principal investigators contributed information 
about almost 120 000 women with breast cancer who had never used menopausal 
hormonal therapies to this individual-participant meta-analysis. We report on the relation 
between menarche and menopause and breast cancer risk, overall, and by oestrogen 
receptor status and by histological subtypes of the tumours, adjusting for possible 
confounding factors. Subgroup results are also shown by various sociodemographic and 
personal characteristics, including year of birth, ethnic origin, parity, age at ﬁ rst birth, 
smoking, alcohol consumption, and body-mass index.
Interpretation
Breast cancer risk increased by a signiﬁ cantly greater factor for every year younger at 
menarche than for every year older at menopause, indicating that menarche and 
menopause may not aﬀ ect breast cancer risk merely by extending women’s total 
reproductive years. Endogenous ovarian hormones are more relevant for oestrogen 
receptor-positive disease than for oestrogen receptor-negative disease and for lobular  
than for ductal tumours.
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These ﬁ ndings conﬁ rm that young age at menarche and 
old age at menopause increase breast cancer risk. Many 
factors known to aﬀ ect breast cancer risk, including 
childbearing patterns, height, and BMI, are also associated 
both with women’s age at menarche and with their age at 
menopause. To ensure as much comparability as possible 
between women with breast cancer and controls, and thus 
to minimise potential confounding, analyses were 
stratiﬁ ed by these factors, and by study, age, year of birth, 
smoking, and alcohol consumption. Additional adjust-
ment by ethnic origin, hormonal contraceptive use, and 
family history of breast cancer altered the excess RR 
estimates by less than 1%. The associations did not vary 
materially by women’s personal characteristics, other than 
BMI among postmenopausal women.
This meta-analysis of individual-participant data 
includes almost all available epidemiological evidence for 
the association between menarche and menopause and 
breast cancer risk. Large numbers of cases were required 
to assess reliably whether the associations diﬀ er by 
tumour type and by characteristics of the aﬀ ected 
women. Combining individual data from many studies 
has the advantage of increasing statistical power and also 
of ensuring that deﬁ nitions across studies are as similar 
as possible. Single studies do not have suﬃ  cient power to 
examine these asso ciations in detail, so reviews based 
solely on the limited published evidence could well be 
susceptible to publication bias. Although availability of 
information about oestrogen receptor status varied 
substantially over time, with most studies done before 
1990 contributing relatively little information, analyses of 
all available data combined were suﬃ  ciently powered to 
describe asso ciations separately within both oestrogen 
receptor-positive and oestrogen receptor-negative 
disease. Another important advantage of this meta-
analysis is that it seeks to review both published and 
unpublished ﬁ ndings, thus avoiding unduly selective 
emphasis on published results or on only some studies.
Women included in these analyses generally reported 
their ages at menarche and at menopause many 
years after the events had occurred. Comparisons of 
information recorded at around the time of menarche 
and menopause with that recalled many years later has 
shown substantial regression to the mean over time, 
especially for recalled age at menarche,16–23 which would 
dilute estimates of RR.23,24 The slight attenuation in the 
estimated RR with attained age thus relects, at least in 
part, misclassiﬁ cation of recalled ages at menarche and, 
to a lesser extent, of recalled age at menopause. There 
might also be systematic diﬀ erences between cases and 
controls in reporting their ages at menopause and 
menarche. Unfortunately insuﬃ  cient information is 
available to correct reliably for this misclassiﬁ cation. 
Since sig niﬁ cant associations were recorded at all ages, it 
is reasonable to conclude that the eﬀ ects of age at 
menarche and age at menopause on breast cancer risk 
persist throughout life.
Since the eﬀ ect on breast cancer risk of 1 year younger 
at menarche is signiﬁ cantly greater than that of 1 year 
older at menopause, these ﬁ ndings suggest that the 
eﬀ ects of each may not be acting merely by lengthening 
the total duration of women’s reproductive years. In most 
populations women’s average age at menarche has been 
declining in successive birth cohorts,25 contributing to 
increasing incidence of breast cancer worldwide.
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